Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...

Pfizer will end global development of its bleeding disorder gene therapy, Beqvez, the Nikkei reported on Thursday.

As the second Trump administration settles in, the U.S.' top pharmaceutical trade group is drafting its ambitions for the ...

Pfizer (NYSE:PFE) has decided to end R&D and marketing activities related to Beqvez, a one-time gene therapy the company has ...

An intriguing battle is brewing in the market to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM). | BridgeBio reported that 1,028 unique prescriptions have been written by 516 ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Pfizer's strong Q4 2024 results showcase growth in cancer drugs and Vyndaqel sales. Learn why PFE stock is a top pick for ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with ...

Pfizer's Super Bowl ad received mixed reactions on social media, but many criticized the pharma giant for saying it will ...

U.S. President Donald Trump is set to meet with top pharmaceutical executives on Thursday, a White House official confirmed. The discussions will focus on Medicare drug price negotiations, pharmacy ...

Pfizer’s Takeda-partnered blood cancer drug Adcetris (brentuximab vedotin) has been approved by the US Food and Drug ...

The pharmaceutical industry’s biggest lobbying group is scheduled to meet with President Donald Trump on Thursday, according ...